Our polymeric drug delivery solutions enable you to create sustained release patient therapies that can lower the dosing frequency for patients. In fact, our biodegradable and biostable TheraPEA™ polyester amides and polyurethanes unlock the potential for unprecedented design freedom of your therapies thanks to tunable properties that can be formulated to work in harmony with even the most challenging APIs.
Controlled linear drug release for up to 6 months.
Broad IP lasting into the mid-2030s.
30-plus years of experience in materials for biomedical applications.
When you choose DSM Biomedical, you can be assured that our solutions are designed to perform safely inside the human body, long-term. We can help you deliver even the most challenging Active Pharmaceutical Ingredients (APIs) in a sustained way – achieving multi-month, controlled release with zero-order degradation across a wide range of indications.
We also support you with with custom process development for different polymeric drug delivery forms; which includes the following, for added peace of mind:
This highly degradable polymer enables you to create formulations with near-linear sustained release rates - from weeks to six months-plus - thus unlocking the potential for lower dosing frequency in patients.
Our biostable polyurethanes have a proven track record in sustained release drug delivery – and are compatible with a wide range of specific Active Pharmaceutical Ingredients (hydrophobic, hydrophilic small molecules, biologics). We can further support you here with:
What is your ideal drug delivery solution? At DSM Biomedical we believe it’s one that benefits all - our partners, patients, and the planet.
Today, our experts are helping to make this a reality through our TheraPEA™ polyester amide platform, which enables sustained drug release, in a more sustainable way. That means multi-month, controlled release; and a zero-order degradation profile – with good correlation in-vitro and in-vivo up to 180 days.
TheraPEA™ is compatible with even the most challenging APIs – unlocking the potential for bold new drug delivery solutions that can improve clinical outcome for patients, deliver better healthcare economics for providers, and boost sustainability by creating significantly less medical waste.
We create sustainable healthcare solutions that deliver tangible and valuable sustainability benefits to our partners – with no compromises on safety or performance.
Pain management, metabolic disease management (Type II diabetes, obesity), non-alcoholic steatohepatitis (NASH), oncology, women’s health, cardiovascular, anti-psychotics, viral disease management (HIV, Hepatitis C); with others evaluated on a case-per-case basis.
We take different approaches, depending on the case (therapeutic area, type of partner).
Please contact us to learn more.
Yes, we do. Over the years we have accrued an enormous amount of knowledge and IP covering both the biocompatible polymers and processes used to create sustained release drug delivery solutions. For more information, contact us.
Looking for more information on how our sustained drug delivery solutions can help you tackle unmet needs?
We understand that medical product development can be a long, winding - and occasionally bumpy road. Rest assured that at DSM Biomedical, we have the proven experience, capabilities, and knowledge to support you every step of the way.
It starts with using a form-fit-function approach based on a comprehensive understanding of how the human body reacts to biomaterials following implantation. This in turn enables us to design materials that are compatible with the body’s physiology and help you develop finished products that can sustain, restore, and repair – all supported by applicable regulatory requirements.
Discover how we can partner with you to create innovative sustained release drug delivery solutions.
Our drug delivery experts are here to help.